Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

被引:239
作者
Forbes, JM
Cooper, ME
Thallas, V
Burns, WC
Thomas, MC
Brammar, GC
Lee, F
Grant, SL
Burrell, LA
Jerums, G
Osicka, TM
机构
[1] Univ Melbourne, Dept Med, Austin & Repatriat Med Ctr, Heidelberg West, Vic, Australia
[2] Austin & Repatriat Med Ctr, Dept Endocrinol, Heidelberg, Vic, Australia
关键词
D O I
10.2337/diabetes.51.11.3274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of ACE inhibition on the formation of advanced glycation end products (AGES) and oxidative stress was explored. Streptozocin-induced diabetic animals were randomized to no treatment, the ACE inhibitor ramipril (3 mg/l), or the AGE formation inhibitor aminoguanidine (1 g/l) and followed for 12 weeks. Control groups were followed concurrently. Renal AGE accumulation, as determined by immunohistochemistry and both serum and renal fluorescence, were increased in diabetic animals. This was attenuated by both ramipril and aminoguanidine to a similar degree. Nitrotyrosine, a marker of protein oxidation, also followed a similar pattern. The receptor for AGES, gene expression of the membrane-bound NADPH oxidase subunit gp91phox, and nuclear transcription factor-kappaB were all increased by diabetes but remained unaffected by either treatment regimen. Two other AGE receptors, AGE R2 and AGE R3, remained unchanged for the duration of the study. The present study has identified a relationship between the renin-angiotensin system and the accumulation of AGES in experimental diabetic nephropathy that may be linked through oxidative stress.
引用
收藏
页码:3274 / 3282
页数:9
相关论文
共 49 条
[31]   AGEs induce oxidative stress and activate protein kinase C-βII in neonatal mesangial cells [J].
Scivittaro, V ;
Ganz, MB ;
Weiss, MF .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2000, 278 (04) :F676-F683
[32]  
Sebeková K, 1999, MINER ELECTROL METAB, V25, P380
[33]   Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats [J].
Soulis, T ;
Cooper, ME ;
Sastra, S ;
Thallas, V ;
Panagiotopoulos, S ;
Bjerrum, OJ ;
Jerums, G .
DIABETOLOGIA, 1997, 40 (10) :1141-1151
[34]   Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment [J].
Soulis, T ;
Cooper, ME ;
Vranes, D ;
Bucala, R ;
Jerums, G .
KIDNEY INTERNATIONAL, 1996, 50 (02) :627-634
[35]   RETARDATION BY AMINOGUANIDINE OF DEVELOPMENT OF ALBUMINURIA, MESANGIAL EXPANSION, AND TISSUE FLUORESCENCE IN STREPTOZOCIN-INDUCED DIABETIC RAT [J].
SOULISLIPAROTA, T ;
COOPER, M ;
PAPAZOGLOU, D ;
CLARKE, B ;
JERUMS, G .
DIABETES, 1991, 40 (10) :1328-1334
[36]   THE RELATIVE ROLES OF ADVANCED GLYCATION, OXIDATION AND ALDOSE REDUCTASE INHIBITION IN THE DEVELOPMENT OF EXPERIMENTAL DIABETIC NEPHROPATHY IN THE SPRAGUE-DAWLEY RAT [J].
SOULISLIPAROTA, T ;
COOPER, ME ;
DUNLOP, M ;
JERUMS, G .
DIABETOLOGIA, 1995, 38 (04) :387-394
[37]   Vascular targets of redox signalling in diabetes mellitus [J].
Spitaler, MM ;
Graier, WF .
DIABETOLOGIA, 2002, 45 (04) :476-494
[38]  
Suzuki D, 1999, J AM SOC NEPHROL, V10, P822
[39]   PREVENTION OF DIABETIC VASCULAR DYSFUNCTION BY GUANIDINES - INHIBITION OF NITRIC-OXIDE SYNTHASE VERSUS ADVANCED GLYCATION END-PRODUCT FORMATION [J].
TILTON, RG ;
CHANG, K ;
HASAN, KS ;
SMITH, SR ;
PETRASH, JM ;
MISKO, TP ;
MOORE, WM ;
CURRIE, MG ;
CORBETT, JA ;
MCDANIEL, ML ;
WILLIAMSON, JR .
DIABETES, 1993, 42 (02) :221-232
[40]   Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 [J].
Tsuchida, K ;
Makita, Z ;
Yamagishi, S ;
Atsumi, T ;
Miyoshi, H ;
Obara, S ;
Ishida, M ;
Ishikawa, S ;
Yasumura, K ;
Koike, T .
DIABETOLOGIA, 1999, 42 (05) :579-588